Stock Track | Maravai LifeSciences Plunges 5.24% Pre-market as Earnings Release Delayed, Revenue Recognition Issues

Stock Track

Feb 25, 2025

Maravai LifeSciences Holdings, Inc. (MRVI) stock plunged 5.24% in pre-market trading on Tuesday, as the company announced the postponement of its Q4 2024 earnings release and a delay in filing its annual report (Form 10-K) for the year ended December 31, 2024.

The life sciences company cited several reasons for the delay, including the need for additional time to assess a potential non-cash impairment charge related to goodwill from a previous acquisition, and an error in revenue recognition that resulted in $3.9 million being recorded in the wrong quarter (Q2 2024 instead of Q3 2024).

MRVI also noted that it requires more time to complete its assessment of the effectiveness of its internal controls over financial reporting, including the remediation of a material weakness in controls over revenue recognition identified by management.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1134711971"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1134711971\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1134711971?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134711971","market":"us","top_or_hot":-1,"title":"Stock Track | Maravai LifeSciences Plunges 5.24% Pre-market as Earnings Release Delayed, Revenue Recognition Issues","media":"Stock Track","content":"<p>Maravai LifeSciences Holdings, Inc. (MRVI) stock plunged 5.24% in pre-market trading on Tuesday, as the company announced the postponement of its Q4 2024 earnings release and a delay in filing its annual report (Form 10-K) for the year ended December 31, 2024.</p>\n\n<p>The life sciences company cited several reasons for the delay, including the need for additional time to assess a potential non-cash impairment charge related to goodwill from a previous acquisition, and an error in revenue recognition that resulted in $3.9 million being recorded in the wrong quarter (Q2 2024 instead of Q3 2024).</p>\n\n<p>MRVI also noted that it requires more time to complete its assessment of the effectiveness of its internal controls over financial reporting, including the remediation of a material weakness in controls over revenue recognition identified by management.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Maravai LifeSciences Plunges 5.24% Pre-market as Earnings Release Delayed, Revenue Recognition Issues</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Maravai LifeSciences Plunges 5.24% Pre-market as Earnings Release Delayed, Revenue Recognition Issues\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-25 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Maravai LifeSciences Holdings, Inc. (MRVI) stock plunged 5.24% in pre-market trading on Tuesday, as the company announced the postponement of its Q4 2024 earnings release and a delay in filing its annual report (Form 10-K) for the year ended December 31, 2024.</p>\n\n<p>The life sciences company cited several reasons for the delay, including the need for additional time to assess a potential non-cash impairment charge related to goodwill from a previous acquisition, and an error in revenue recognition that resulted in $3.9 million being recorded in the wrong quarter (Q2 2024 instead of Q3 2024).</p>\n\n<p>MRVI also noted that it requires more time to complete its assessment of the effectiveness of its internal controls over financial reporting, including the remediation of a material weakness in controls over revenue recognition identified by management.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRVI","symbol_name":"Maravai LifeSciences Holdings, Inc.","start_time":0,"source_url":"","article_id":"1134711971","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134711971","pubTimestamp":1740481589,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Maravai LifeSciences Holdings, Inc.  stock plunged 5.24% in pre-market trading on Tuesday, as the company announced the postponement of its Q4 2024 earnings release and a delay in filing its annual report  for the year ended December 31, 2024.The life sciences company cited several reasons for the delay, including the need for additional time to assess a potential non-cash impairment charge related to goodwill from a previous acquisition, and an error in revenue recognition that resulted in $3.9","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRVI":"Maravai LifeSciences Holdings, Inc."},"translate_title":"由于财报发布延迟、收入确认问题，Maravai LifeSciences盘前暴跌5.24%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRVI":1},"content_text":"Maravai LifeSciences Holdings, Inc. (MRVI) stock plunged 5.24% in pre-market trading on Tuesday, as the company announced the postponement of its Q4 2024 earnings release and a delay in filing its annual report (Form 10-K) for the year ended December 31, 2024.\nThe life sciences company cited several reasons for the delay, including the need for additional time to assess a potential non-cash impairment charge related to goodwill from a previous acquisition, and an error in revenue recognition that resulted in $3.9 million being recorded in the wrong quarter (Q2 2024 instead of Q3 2024).\nMRVI also noted that it requires more time to complete its assessment of the effectiveness of its internal controls over financial reporting, including the remediation of a material weakness in controls over revenue recognition identified by management.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}